Cancer Immunology
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributio...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2021 |
| Language: | English |
| Physical Description: | 1 electronic resource (316 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 03966nam-a2201249z--4500 | ||
|---|---|---|---|
| 001 | 993545641404498 | ||
| 005 | 20231214132942.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202201s2021 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000042398 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/77108 | ||
| 035 | |a (EXLCZ)995400000000042398 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Subramanian, Subree |4 edt | |
| 245 | 1 | 0 | |a Cancer Immunology |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (316 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a NKG2D | ||
| 653 | |a CAR T | ||
| 653 | |a IL-7 | ||
| 653 | |a prostate cancer | ||
| 653 | |a cell therapy | ||
| 653 | |a CD19-CAR-T | ||
| 653 | |a B cell aplasia | ||
| 653 | |a KIR | ||
| 653 | |a PD-1 | ||
| 653 | |a inhibitory CAR | ||
| 653 | |a tumor-infiltrating lymphocytes | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a immunotherapy | ||
| 653 | |a NK cells | ||
| 653 | |a cancer stem cells (CSCs) | ||
| 653 | |a antibody-dependent cellular cytotoxicity (ADCC) | ||
| 653 | |a differentiation | ||
| 653 | |a cytotoxicity | ||
| 653 | |a IFN-γ | ||
| 653 | |a osteoclasts | ||
| 653 | |a MICA/B mAb | ||
| 653 | |a DNA methylation | ||
| 653 | |a RNA methylation | ||
| 653 | |a S-adenosylmethionine (SAM) | ||
| 653 | |a cancer | ||
| 653 | |a innate immunity | ||
| 653 | |a adaptive immunity | ||
| 653 | |a T cells | ||
| 653 | |a m6A | ||
| 653 | |a PD-L1 | ||
| 653 | |a resistance | ||
| 653 | |a immune checkpoints | ||
| 653 | |a cancer vaccine | ||
| 653 | |a combination immunotherapy | ||
| 653 | |a TCR diversity | ||
| 653 | |a organ transplantation | ||
| 653 | |a carcinoma | ||
| 653 | |a epidemiologic studies | ||
| 653 | |a immunosuppression | ||
| 653 | |a CTLA-4 | ||
| 653 | |a Treg cells | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a CD28 | ||
| 653 | |a antigen-presenting cells | ||
| 653 | |a IL15 | ||
| 653 | |a colon cancer | ||
| 653 | |a melanoma | ||
| 653 | |a uveal | ||
| 653 | |a BAP1 | ||
| 653 | |a anti-PD-1 | ||
| 653 | |a anti-CTLA-4 | ||
| 653 | |a TIL | ||
| 653 | |a classical and endemic Kaposi Sarcoma | ||
| 653 | |a systemic treatment | ||
| 653 | |a multi-state modelling | ||
| 653 | |a treatment free interval | ||
| 653 | |a chemotherapy | ||
| 653 | |a interferon | ||
| 653 | |a triple negative breast cancer | ||
| 653 | |a immunomodulation | ||
| 653 | |a bispecific antibody | ||
| 653 | |a sortase A | ||
| 653 | |a chemo-enzymatic approach | ||
| 653 | |a anti-CD20 antibody | ||
| 653 | |a Fab | ||
| 653 | |a BiFab | ||
| 653 | |a colorectal cancer | ||
| 653 | |a dendritic cells | ||
| 653 | |a Atypical Chemokine Receptor 4 (ACKR4) | ||
| 653 | |a T-cell priming | ||
| 653 | |a immune checkpoint blockade | ||
| 653 | |a primary liver cancer | ||
| 653 | |a kynurenine pathway | ||
| 653 | |a immune evasion | ||
| 653 | |a indoleamine 2,3 dioxygenase 1 | ||
| 653 | |a tryptophan 2,3 dioxygenase 2 | ||
| 653 | |a IDO inhibitor | ||
| 653 | |a antigen presenting cells | ||
| 776 | |z 3-0365-2573-4 | ||
| 776 | |z 3-0365-2572-6 | ||
| 700 | 1 | |a Zhao, Xianda |4 edt | |
| 700 | 1 | |a Subramanian, Subree |4 oth | |
| 700 | 1 | |a Zhao, Xianda |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:37:43 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338004980004498&Force_direct=true |Z 5338004980004498 |b Available |8 5338004980004498 | ||